Prospects for the therapeutic use of antigene oligonucleotides

Cancer Investigation
L J Maher

Abstract

An outgrowth of classic nucleic acid interaction studies, oligonucleotide-directed triple helix formation is a unique method for creating highly specific chemical ligands that recognize and bind to particular sequences of duplex DNA. Under permissive conditions, these oligonucleotide-based compounds can approach or exceed the binding affinity and sequence specificity of natural DNA-binding proteins. Triple helix recognition has been found to be useful in certain cell-free applications including precise chromosome fragmentation. It has been proposed that such oligonucleotides could also form the basis for gene-targeted (antigene) drugs that might repress transcription from undesired genes in living cells. However, current strategies for oligonucleotide-directed triple helix formation suffer from important constraints involving requirements for stabilizing binding conditions, restrictions on permitted target sequences, and inefficient nuclear delivery of oligonucleotides. Implementation of oligonucleotide-directed triple helix formation as a viable approach to cancer therapy must therefore await clever solutions to a series of fascinating problems.

References

Oct 1, 1976·Nucleic Acids Research·S ArnottP J Smith
Jan 1, 1992·Methods in Enzymology·S A Strobel, P B Dervan
Dec 11, 1992·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·L J Maher
Jan 1, 1992·Progress in Biophysics and Molecular Biology·Y K Cheng, B M Pettitt
Dec 1, 1992·The American Journal of the Medical Sciences·J E Gee, D M Miller
Dec 25, 1992·Nucleic Acids Research·C A Laughton, S Neidle
Dec 30, 1992·Biochemical and Biophysical Research Communications·C RossS L Broitman
Aug 11, 1992·Nucleic Acids Research·K H JohnsonM E Hogan
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·C GiovannangéliC Hélène
May 26, 1992·Biochemistry·E WangJ Feigon
Jun 19, 1992·Science·J L MergnyC Hélène
Jul 11, 1992·Nucleic Acids Research·T ItoC R Cantor
May 11, 1992·FEBS Letters·M ShimizuE Ohtsuka
Aug 30, 1990·Nature·A D Ellington, J W Szostak
Sep 20, 1991·Science·D H PeiP G Schultz
Jan 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G Duval-ValentinC Hélène
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C Hélène
Jan 1, 1991·Bioconjugate Chemistry·P E Nielsen
Sep 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E H PostelM E Hogan
Sep 25, 1991·Nucleic Acids Research·D A Horne, P B Dervan
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·R W Roberts, D M Crothers
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S L YoungJ J Toole

❮ Previous
Next ❯

Citations

Apr 5, 2002·Chembiochem : a European Journal of Chemical Biology·Günther N GrimmClaude Hélène
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·C Giovannangeli, C Hélène
Dec 25, 2007·Oligonucleotides·Zhaoyang YeRam I Mahato
May 1, 1996·Nucleic Acids Research·W M Olivas, L J Maher
Jun 22, 1999·Nucleic Acids Research·A DebinF Svinarchuk
Dec 24, 1998·Nucleic Acids Research·J Selvasekaran, K D Turnbull
Dec 20, 2002·Nucleic Acids Research·Patrizia AlbertiJian-Sheng Sun
Aug 5, 2008·Nucleic Acids Research·Maria DucaPaola B Arimondo
Jul 14, 2010·Biochemistry. Biokhimii︠a︡·Cheng-Yong ZhouPin Yang
Aug 30, 2007·Critical Reviews in Therapeutic Drug Carrier Systems·Kun Cheng, Ram I Mahato
Jan 7, 1997·Proceedings of the National Academy of Sciences of the United States of America·C GiovannangeliC Helene
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·D H OhP C Hanawalt
Mar 21, 2002·Expert Opinion on Therapeutic Targets·T KindlerT Fischer
Jul 25, 2003·Expert Review of Molecular Diagnostics·Vladimir N Potaman
Nov 22, 2005·Expert Opinion on Drug Delivery·Ram I MahatoRamareddy V Guntaka
Aug 20, 2003·The Journal of Clinical Investigation·Michael M Seidman, Peter M Glazer
Nov 12, 2003·Nucleosides, Nucleotides & Nucleic Acids·Mrinalkanti KunduMichael M Seidman
Sep 21, 2001·Nucleosides, Nucleotides & Nucleic Acids·G N GrimmC Hélène
Mar 27, 2018·Chembiochem : a European Journal of Chemical Biology·Dattatraya Uttam Ukale, Tuomas Lönnberg
May 25, 2005·Chembiochem : a European Journal of Chemical Biology·Thibaut MichelJean-Jacques Vasseur
Jun 5, 2001·The Journal of Biological Chemistry·N PuriM M Seidman
Sep 20, 2000·The Journal of Biological Chemistry·F L LinM M Seidman
Jan 23, 2003·The Journal of Biological Chemistry·Alokes MajumdarMichael M Seidman
May 12, 2000·Biochimica Et Biophysica Acta·D PraseuthC Hélène

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.